chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a registered nurse regarding a currently 14 year old male patient with attention deficit hyperactivity disorder and an unspecified drug reactions or allergies. On an unknown date, the patient was vaccinated with his first dose of GARDASIL (dose, lot number and expiration date were not provided) along with an unspecified Hepatitis A vaccine (manufacturer unknown) (dose, lot number and expiration date were not provided). Concomitant therapies included an unspecified meningococcal vaccine (dose and lot number were not provided) and unspecified medication for attention deficit hyperactivity disorder. On an unknown date, the patient experienced syncope within minutes of being administered the GARDASIL. The patient initially became light headed, and then experienced syncope. The patient still felt weak after recovering from the fainting spell. An ambulance was called and the patient was taken to the hospital. The patient was observed in the Emergency room and was given an electrocardiogram (EKG) with no abnormal findings. The patient was then sent home. The Patient was taken to the hospital Emergency room again later in the same day complaining of back pain, chest pain and coughing and shortness of breath on an unspecified date. He was admitted to hospital where he received fluids and was observed. He was transferred to another hospital, on an unspecified date and discharged on an unspecified date with a diagnosis of a "viral infection". Patient is still complaining of cough and asthma-like symptoms. The patient sought medical attention, was to emergency room. At the time of the report, the patient had not recovered from the adverse event (viral infection). Additional information has been requested.
Dizziness, Headache, Fever & NauseaVomiting Narrative:
Hospitalized 11/17/2021; COVID-19 positive 11/17/2021; fully vaccinated plus booster  BRIEF OVERVIEW: Discharge Provider: MD Primary Care Provider: MD Admission Date: 11/17/2021 Discharge Date: 11/22/2021 Presenting Problem: Acute kidney injury DETAILS OF HOSPITAL STAY: HOSPITAL COURSE: Patient is a 68 y.o. male with past medical history of OHT 7/9/2021, CKD3, HTN who presents with AKI, cough, diarrhea, fatigue, fevers and chills. Patient had diarrhea 11/11-11/12 but resolved 11/13. Had done CMV testing and stool samples as outpt without any findings. Felt ok 11/15 and went to cardiac rehab. Then 11/16 patient developed cough, fevers and chills and had recurrent diarrhea. He was directed to the ED for further evaluation. Labs revealed Na 129, Cr 4.8 (baseline around 2.9-3 recently), BUN 73, procal 0.31, WBC 3.95, Hgb 7.9, tac level 4.4 on 11/5. Patient found to be COVID19+. CXR suggestive of right middle lobe pneumonia. Patient remains comfortable on room air.   Recent admission 10/4-10/9/21 due to AKI on CKD and mild leukopenia. After initial evaluation, his hypovolemic hyponatremia was felt to be the result of CNI nephrotoxicity with sodium and volume completion. Most recent RHC revealed hypovolemia, so he was liberalized to 3L/2g diet, to which he has been strictly adherent and still remained volume depleted. Nephrology consulted and the patient's sodium level and renal function improved with gentle hydration with NS.  Urine studies were collected to include 24 hour protein. With concern for CNI toxicity, his tacro goal and dose were decreased and everolimus was added with new goals of Tacro 3-5 and Evero 5-7. Due to being hypovolemic and hyponatremic, his home PRN lasix was discontinued upon discharge.  Discharge weight 77.2kg during this prior hospitalization.  For his COVID pneumonia, he was treated with monoclonal antibody, but do not require Decadron steroids.  He is also treated for concurrent community-acquired pneumonia completing 3 days of azithromycin 5 days of IV ceftriaxone.  He had lab findings significant for leukopenia, anemia, and AKI.  He required 2 units of blood transfusion on 11/21.  Stool sample for hemoccult blood pending.  Hematology was consulted for leukopenia and anemia.  Nephrology was consulted who made medication adjustments. Nephrology will plan to see as outpatient.  Patient was continued on tac and goal 2-4 with tac level 6.6 on day of discharge. Everolimus was resumed at discharge and goal 4-6. Patient as placed on atovaquone given AKI during hospitalization and changed back to bactrim at discharge with improving kidney function and the high cost of atovaquone.  Patient seen by me on day of discharge and felt safe for discharge home. Patient and Dr. in agreement.
With both vaccines I had pain going up my neck. After first dose, I had a runny nose. Second vaccine, congestion, earaches and runny nose. I have very little energy. Prior to vaccine I was go, go, go. Claritin twice a day, Benadryl at night to dry up the ears. I was prescribed Prednisone and I can't take it. I tested positive for COVID-19 04/23/2022. I was retested at my doctor's office 04/26 and it was positive. The doctor prescribed inhaler and ipratropium bromide, Mucinex.
Couldn't get out of bed; Bedbound and can't stand up or move; Bedbound and can't stand up or move; In a lot of pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 74 year-old female patient received bnt162b2 (BNT162B2), administration date 15Apr2021 (Batch/Lot number: unknown) at the age of 74 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious) with onset 2021, outcome "unknown", described as "Couldn't get out of bed"; DYSSTASIA (non-serious), MOVEMENT DISORDER (non-serious) all with onset 2021, outcome "unknown" and all described as "Bedbound and can't stand up or move"; PAIN (non-serious) with onset 2021, outcome "unknown", described as "In a lot of pain".  Additional Information: Reason for no lot number: of Pfizer Covid Vaccine: Caller unwilling to complete the report.  Follow- up#1(06-MAY-2021): This is a follow-up spontaneous report from a contactable consumer. This consumer (caregiver) reported for a 74-year-old female patient which included that New events Activities of daily living impaired, Difficulty in standing, Movement disorder, Pain was added, other medical information was added. Narrative was updated.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt received Pediatric (Orange cap) Pfizer vaccine. total amount given was 0.3 mL NOT 0.2 mL. pt and PCP aware.
Information has been received from a healthcare worker referring to an adult patient of unknown age and gender. The patient's medical history and concomitant medication were unknown. On 02-DEC-2016, the patient with Sjogren's syndrome was vaccinated with VARIVAX (dose and route unknown, lot # L025210, expiration date: 07-JUL-2017) for prophylaxis rather than ZOSTAVAX. No adverse effect was reported. Additional information has been requested.
Patient began feeling ill 1/3/22. Went to urgent care and was treated for nausea. PT continued to feel worse. Went to the ED 1/9/22. Was admitted 1/9/22-1/12/22 for myocarditis. Follows with cardiology since hospitilization.
Gave school IZ's 5/26/09, when child came back fur PPD reading father states child's leg had some redness we examined it and measured it.
Patient reported rash on her forehead that do not tingle, is itchy, and is bilateral.
stuffy head; trouble breathing; sinus headache; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm), NASAL CONGESTION (stuffy head), DYSPNOEA (trouble breathing) and SINUS HEADACHE (sinus headache) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21-2A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore arm). On 28-Mar-2021, the patient experienced NASAL CONGESTION (stuffy head), DYSPNOEA (trouble breathing) and SINUS HEADACHE (sinus headache). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) at an unspecified dose and frequency and IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency. On 27-Mar-2021, PAIN IN EXTREMITY (sore arm) had resolved. On 28-Mar-2021, NASAL CONGESTION (stuffy head) and SINUS HEADACHE (sinus headache) had resolved and DYSPNOEA (trouble breathing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.
NOTHING OCCURED TO PATIENT, PATIENT WAS GIVEN 0.1ML OF PFIZER
Appendicitis,  ruptured aappendix resulting in hospitalization and appendectomy 9/6/21. Complications of internal bleeding which necessitated transfusion and a second surgery. JP drain. Contracted c diff and thrush due to antibiotics. Developed anemia due to hemoglobin loss. Had treatment for c diff. Still with JP drain as of 10/1/21. Taking iron to treat low hemoglobin.
fever; chills; This is a spontaneous report from a contactable consumer or other non-hcp (Patient). A 81-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection; Batch/Lot Number: Unknown, Expiration date: Unknown) via an unspecified route of administration (age at vaccination 81-year) on an unspecified date as dose 2, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Historical vaccine included first dose of BNT162B2 administered on an unspecified date for COVID-19 immunization. On an unspecified date the patient experienced fever, and chills. It was reported that patient stated that she got her 2nd COVID-19 vaccine, and she had some fever and chills, but she was feeling better on the day of reporting from it. The clinical outcome of the events was resolving.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Extreme headache and ear ringing Headache resolved within 24 hrs, ear ringing has not stopped  Got worse after the second vaccine, second dose received on May 18th, lot number EW0173
Teacher found client at locker squatting down called her by name did not respond eyes up in head lids closed became rigid hands and arms curled up. Became very white teacher shook shoulder called name. Came out of it. Not fully conscious. Did recognize teacher pupils dilated also even after resting on cot in nurses office.
Pain around injection site; Severe fatigue; mild muscle/ joint pain; mild muscle/ joint pain; Mild nausea; This is a spontaneous report from a non-contactable consumer, the patient. An 18-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6995), via an unspecified route of administration in the right arm on 25Mar2021 at 08:30 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. Concomitant medications received within two weeks of vaccination included methylphenidate hydrochloride (RITALIN), Sertraline hydrochloride (ZOLOFT) and testosterone (MANUFACTURER UNKNOWN) for unknown indications from unknown date. On 25Mar2021 at 12:00, the patient experienced pain around injection site, severe fatigue, mild muscle/ joint pain and mild nausea. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of vaccination site pain, severe fatigue, muscle pain, joint pain and mild nausea was unknown.   No follow-up attempts are possible. No further information is expected.
Tiredness; Pain in arm at injection site; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 12Apr2021 at 15:00 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. Concomitant medications included ascorbic acid, cyanocobalamin, ergocalciferol, nicotinamide, pyridoxine hydrochloride, retinol, riboflavin, thiamine mononitrate (ONE-A-DAY) and amlodipine (MANUFACTURER UNKNOWN) from an unknown start date for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 21:00 the patient experienced pain in arm at vaccination site and tiredness. Since the vaccination, the patient had not been tested for COVID-19. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the event pain in arm at vaccination site was recovered on 13Apr2021 after the duration of 24 hours. The clinical outcome of the event tiredness was recovering at the time of reporting.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
On both my first and second shot I got really bad brain fog. I went to the ER after my first shot on June 29, 2021 but they told me it was a psychological thing and that I was freaking myself out and that it was not vaccine related but I knew the at wasn?t the case. After my first shot the pressure in my head remained for about a week and the brain fog and vision/auditory issues only occurred on the first day mainly. On my second shot today (07/20/2021) it occurred again and so I know it?s vaccine related, not psychological. On both shots it was an immediate reaction. As soon as the person began to inject the vaccine into me I would feel immediate pressure in my head (on the first shot it felt like the vaccine literally traveled to my fingertips in my left arm and up into my head, it was very strange). Then about 2-5 minutes after I got the vaccine on both occasions my vision became filled with floaters and my coherency decreased. The first vaccine was the worst as the floaters stayed longer and my vision would go in and out of bluriness more. On the second shot the floaters were very obvious for the first hour and then slowly decreased over time but it is currently 6 hours after my shot right now and I still see a couple. On my second shot my vision did blur but not as bad. Both times I felt tremendous pressure in my head and I couldn?t think straight or focus. My speech was very slow and the ordering of my words were inaccurate. My texting was bad because I couldn?t spell and the structure of my sentences was incorrect. I have issues putting words together to say what I want to say and I can?t concentrate. Both times I have stared at a wall in fixation for hours which is not normal. It?s not so much as a headache, just a lot of pressure and I?ve never experienced it with anything else in my life. After my second dose I was also extremely exhausted but could not sleep because of the pressure in my head. My memory is also affected as I cannot remember things very well. It takes me about 30 seconds to understand what someone says because I just can?t think. I feel like my cognitive processes are faulty. It?s like a very intense brain fog that affects my vision and on the first vaccine also affected my hearing as stuff sounded muffled.
Vaccine that had experienced a temperature excursion was given as 2nd dose; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT STORAGE ERROR (Vaccine that had experienced a temperature excursion was given as 2nd dose) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Sep-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Sep-2021, the patient experienced PRODUCT STORAGE ERROR (Vaccine that had experienced a temperature excursion was given as 2nd dose). On 23-Sep-2021, PRODUCT STORAGE ERROR (Vaccine that had experienced a temperature excursion was given as 2nd dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were reported.
Client received varicella vaccination, RN unaware of pregnancy at time of vaccination. No adverse reaction noted at time of vaccination.
pain in arm/Sore Arm; strong pain on the left side, from the low back through the thigh; Lower Back pain; head feeling weird; she then states that it is a little dizzy; This is a spontaneous report from a contactable consumer. A 64-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection. Lot Number: EL9264), dose 1 via an unspecified route of administration, administered in left arm on 13Feb2021 at 13:50 as 1st dose, single for covid-19 immunization. Patient's medical and concomitant medication history were not reported. The patient experienced pain in arm/sore arm, strong pain on the left side, from the low back through the thigh, lower back pain on 13Feb2021 and head was little weird, it's not dizzy, it's just not feeling normal, patient had no headache, patient then states that it was a little dizzy on 14Feb2021. It was reported that, "She took ibuprofen on Saturday and just 1 pill 600mg. She also put a cold pack on the arm because it was sore at night and she couldn't sleep well and that helped her. Yesterday morning she took another motrin. While her head feeling weird since she took medicine ibuprofen about 1-2 hours ago, right now she is a little better". The outcome of event was recovered for pain in extremity, back pain, head discomfort and unknown for the rest of the events.   Follow-up (12May2021): Follow-up attempts completed. No further information expected.
Headache, Myalgia, CHILLS/FATIGUE Narrative:  Other Relevant History:
Information has been received from a health professional concerning a 13 week old male who on the morning of 8/17/06 was vaccinated PO with the first dose of Rotavirus G1 G2 G3 G4 P1 reassortant vaccine live (human Bovine). Concomitant vaccinations administered on that same day and time included the first IM dose of Pediarix (lot AC21B059AA), the first IM dose of ActHib (lot UE918AA) and the first IM dose of Prevnar (lot B08682A). It was reported that on the morning of 8/17/06, six hours after being vaccinated, the pt experienced a high fever up to 102-103. The pts temp continued to rise up to 105. Despite being treated with Tylenol and Motrin, the pt went to the ER for evaluation. Blood cultures, urine cultures and a chest x ray were all neg. Subsequently, the pts fever resolved. No further information is available.
After vaccine was administered, patient developed red spots on her face. She was advised to take BENADRYL. She was advised to call 911 if symptoms persisted.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a patient who received BEXSERO. On an unknown date, the patient received BEXSERO at an unknown dose. On an unknown date, unknown after receiving BEXSERO, the patient experienced injection site pain, injection site mass, injection site induration and injection site swelling. On an unknown date, the outcome of the injection site pain, injection site mass, injection site induration and injection site swelling were unknown. It was unknown if the reporter considered the injection site pain, injection site mass, injection site induration and injection site swelling to be related to BEXSERO. Additional details were provided as follows: The age at vaccination was not reported. The health care professional had limited information. No patient or product information was reported. It was stated that there was three patients involved but no more information provided. This was one of the 3 cases reported by same reporter.
my left deltoid had a spasm with the injection; my thumb, pointer and middle fingers began having intermittent numbness and tingling; my thumb, pointer and middle fingers began having intermittent numbness and tingling; ongoing intermittent, positional pain in my left shoulder radiating to the left side of my neck; This is a spontaneous report from a contactable Nurse. A 37-years-old non-pregnant female patient received second dose of bnt162b2 (BNT162B2, solution for injection; Batch/Lot Number: EN6200), dose 2 via intramuscular route of administration, administered in Arm Left on 26Feb2021 16:00 as dose 2, single (at the age of -37 years) for covid-19 immunisation at Hospital. Medical history included migraine headache and covid 19 from an unknown date and unknown if ongoing. Patient's concomitant medications were not reported. Historical vaccine included received first dose of BNT162B2 (COMIRNATY, solution for injection, Batch/Lot Number: was not reported), via an unspecified route of administration, on an unspecified date for COVID-19 immunization. Prior to vaccination, the patient was diagnosed with COVID-19. Post vaccination,  patient was not tested with COVID-19. Known allergies were reported as none. No other vaccine was given in four weeks. The first injection was fine. Patient had back pain for about 24 hours after wards. On 26Feb2021 20:00 the patient experienced left deltoid had a spasm with the injection, my thumb, pointer and middle fingers began having intermittent numbness and tingling, ongoing intermittent, positional pain in my left shoulder radiating to the left side of my neck. The patient did not receive any treatment for the events. The outcome of the event was not recovered.   No follow-up attempts are possible. No further information is expected.
itchy around the injection site; redness at the injection site; hard at the injection site; Little warm; This spontaneous case was reported by a consumer and describes the occurrence of   in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) for Cholesterol, ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) and LEVOCETIRIZINE DIHYDROCHLORIDE (XYZAL) for an unknown indication.    On 10-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Information was received from a medical assistant regarding an unspecified number of patients (demographics not provided). On an unknown date, an unspecified amount of doses of VARIVAX (Merck) (route of administration not provided) were administered to an unspecified amount of patients. No adverse effect reported. No further information was provided. This is one of several reports from the same reporter. Additional information has been requested.